BSE - Delayed Quote INR
Genpharmasec Ltd (GENPHARMA.BO)
2.1900
-0.0100
(-0.45%)
At close: June 13 at 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
337,218
337,218
304,057
252,834
266,112
Cost of Revenue
295,486
295,486
242,325
233,974
265,652
Gross Profit
41,732
41,732
61,732
18,860
460
Operating Expense
18,002
18,002
8,063
18,088
12,908
Operating Income
23,730
23,730
53,669
772
-12,448
Net Non Operating Interest Income Expense
-4,348
-4,348
-4,091
-253
650
Pretax Income
18,802
18,802
2,506
2,816
-4,431
Tax Provision
7,258
7,258
4,199
-8,432
-2,337
Net Income Common Stockholders
12,312
12,312
-1,693
11,248
-2,094
Diluted NI Available to Com Stockholders
12,312
12,312
-1,693
11,248
-2,094
Basic EPS
0.01
--
0.01
0.02
-0.01
Diluted EPS
0.01
--
0.01
0.02
-0.01
Basic Average Shares
553,719.7000
--
553,719.7000
461,082.6440
461,080.4290
Diluted Average Shares
553,719.7000
--
553,719.7000
461,082.6440
461,080.4290
Rent Expense Supplemental
--
--
1,536
1,464
1,044
Total Expenses
313,488
313,488
250,388
252,062
278,560
Net Income from Continuing & Discontinued Operation
12,312
12,312
-1,693
11,248
-2,094
Normalized Income
12,312
12,312
-1,693
10,126.6000
-7,059.1000
Interest Income
--
--
4,731
307
650
Interest Expense
4,348
4,348
4,091
560
0
Net Interest Income
-4,348
-4,348
-4,091
-253
650
EBIT
23,150
23,150
6,597
3,376
-4,431
EBITDA
31,265
31,265
7,018
3,573
-4,289
Reconciled Cost of Revenue
295,486
295,486
242,325
233,974
265,652
Reconciled Depreciation
8,115
8,115
421
197
142
Net Income from Continuing Operation Net Minority Interest
12,312
12,312
-1,693
11,248
-2,094
Total Unusual Items Excluding Goodwill
--
--
-5,074
1,602
7,093
Total Unusual Items
--
--
-5,074
1,602
7,093
Normalized EBITDA
31,265
31,265
7,018
1,971
-11,382
Tax Rate for Calcs
0.0004
0.0004
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
0
0
0
480.6000
2,127.9000
3/31/2022 - 12/30/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade